Skip to main content
Atrás
ACRS logo

Aclaris Therapeutics, Inc.

Calidad de datos: 100%
ACRS
NASDAQ Healthcare Medical - Diagnostics & Research
CEO: Neal S. Walker Employees: 61 IPO: Oct 06, 2015
Precio
$4.20
Cambio
▲ $0.06
1.45%
Cap. Mercado
506.50M
Rango del Día
$4.01 $4.22
Rango de 52 Semanas
$1.05 $4.89
Volumen
892,765
Promedio 50D / 200D
$3.52
$2.49
Cierre Anterior
$4.14

Quick Summary

Puntos Clave

Revenue grew 3.72% annually over 5 years — modest growth
Debt/Equity of 0.02 — conservative balance sheet
Negative free cash flow of -47.11M
PEG of 0.08 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 61.91%
Capital efficient — spends only 1.42% of revenue on capex

Crecimiento

Revenue Growth (5Y)
3.72%
Below sector avg (9.58%)
Revenue (1Y)-58.19%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-50.20%
Below sector avg (3.46%)
ROIC-54.45%
Net Margin-829.58%
Op. Margin-975.91%

Seguridad

Debt / Equity
0.02
Below sector avg (0.23)
Current Ratio5.28
Interest Coverage0.00

Valoración

P/E Ratio
-7.80
Below sector avg (0.22)
Forward P/EN/A
P/B Ratio4.91
EV/EBITDAN/A
Dividend Yield0.00%

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (640 pares)

Métrica Acción Mediana del Sector
P/E -7.8 0.2
P/B 4.9 2.9
ROE % -50.2 3.5
Net Margin % -829.6 3.9
Rev Growth 5Y % 3.7 9.6
D/E 0.0 0.2

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

All Fundamental Metrics

Growth
Revenue Growth (1Y) -58.19% Revenue Growth (3Y) -49.96%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 3.72% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 7.83M Net Income (TTM) -64.92M
ROE -50.20% ROA -40.46%
Gross Margin 73.28% Operating Margin -975.91%
Net Margin -829.58% Free Cash Flow (TTM) -47.11M
ROIC -54.45% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.02 Current Ratio 5.28
Interest Coverage 0.00
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -7.80 Forward P/E N/A
P/B Ratio 4.91 P/S Ratio 64.72
PEG Ratio 0.08 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -9.30%
Market Cap 506.50M Enterprise Value 488.66M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 7.83M 18.72M 31.25M 29.75M 6.76M
Net Income -64.92M -132.07M -88.48M -86.91M -90.87M
EPS (Diluted) -0.53 -1.71 -1.27 -1.33 -1.60
Gross Profit 5.74M 15.93M 13.17M 17.79M 2.05M
Operating Income -76.38M -141.93M -97.36M -89.85M -89.72M
EBITDA -64.47M -51.72M -115.45M -84.36M -64.46M
R&D Expenses 52.65M 33.59M 98.38M 77.81M 43.81M
SG&A Expenses 21.97M 22.20M 31.10M 25.13M 23.62M
D&A 454,000.0 807,000.0 863,000.0 797,000.0 923,000.0
Interest Expense 0.0 0.0 0.0 0.0 0.0
Income Tax 0.0 0.0 -367,000.0 0.0 0.0

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 160.46M 220.33M 197.41M 254.60M 251.21M
Total Liabilities 57.38M 64.77M 40.23M 56.98M 53.87M
Shareholders' Equity 103.08M 155.55M 157.18M 197.62M 197.34M
Total Debt 2.12M 0.0 426,000.0 684,000.0 693,000.0
Cash & Equivalents 19.96M 24.57M 39.88M 45.28M 27.35M
Current Assets 151.36M 125.95M 128.86M 231.55M 205.03M
Current Liabilities 28.65M 31.60M 30.95M 21.94M 22.93M